Perspective
WuXi STA is proceeding with a major multi-site, global expansion plan to enhance its manufacturing capabilities and capacities. Yu Lu, the Chief Business Officer of WuXi STA and Head of WuXi…
WuXi STA is proceeding with a major multi-site, global expansion plan to enhance its manufacturing capabilities and capacities. Yu Lu, the Chief Business Officer of WuXi STA and Head of WuXi TIDES, detailed the expansion efforts across several key sites at the DCAT Member Company Announcement Forum held on March 18th, 2024, at DCAT Week.
The expansion efforts across several key sites, including the unveiling of its 169-acre active pharmaceutical ingredient (API) manufacturing facility in Taixing, China, alongside existing drug-product manufacturing facilities in Wuxi City, China, and Couvet, Switzerland, and forthcoming sites in Middletown, Delaware, and Tuas, Singapore.
Keep reading
Process mass intensity (PMI) is one of the most important metrics in sustainable manufacturing. It measures the total mass of raw materials required to produce a given mass of product. In…
As GLP-1 receptor agonists continue to redefine treatment for metabolic diseases, drug developers are racing to bring new and more complex therapies to the clinic. But innovation alone is…
A new publication by MSD in Organic Process Research & Development details the process development and large-scale manufacturing of the key Northern Fragment of Enlicitide Decanoate.
How can we help?
Tell us where your molecule is today — discovery, CMC, or commercial supply — and we will map the fastest credible route to patients.
Small molecule projects? WuXi STA